Indianapolis, IN Clinical Trials Report — June 2026

For Indianapolis residents interested in contributing to medical research, June 2026 presents both urgent opportunities and exciting new avenues for participation. Across Indianapolis, IN, 838 clinical trials are currently recruiting participants at 377 research facilities. This month, a significant number of studies are nearing their enrollment deadlines, making prompt action essential for those considering participation.

Act Now: Trials Closing Soon

A total of 53 clinical trials are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 7 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Advanced solid tumor (2 trials)
• Cystic fibrosis (CF) (2 trials)
• Pain (2 trials)
• Acute liver injury (1 trial)
• Adult thoracic procedures (1 trial)
• Adult urological procedures (1 trial)
• Adult surgical procedures (1 trial)
• Alcohol use disorder (1 trial)
• Alzheimer's disease (1 trial)
• Amyotrophic lateral sclerosis (1 trial)

New Research Opportunities Emerge in Indianapolis

This month, Indianapolis saw the opening of 18 new clinical trials, a notable increase from the 10 trials that launched in May 2026. This surge in new research reflects a dynamic and growing clinical trial landscape in the city.

Spotlight on Notable New Trials

June brings several high-profile new trials to Indianapolis, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• AstraZeneca is sponsoring a notable Phase 3 study, NCT07667803, "A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM." This global, randomized, double-blind, parallel-group, multicenter study aims to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise in 4,500 participants.
• Novo Nordisk A/S is leading another Phase 3 study, NCT07668414, "A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide." This study seeks 650 participants to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.
• Indiana University is sponsoring NCT07640139, "Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes." This observational study aims to identify the impact of incretin-based obesity medications (e.g., GLP-1 and GLP-1/GIP) on health and economic outcomes among adults with employer-provided health insurance, involving 125,000 participants.
• Also from Indiana University, NCT07663136, "Finding Immune Nascent Type 1 Diabetes," aims to understand how many individuals who previously participated in the Indiana Biobank will return a type 1 diabetes home screening kit based upon different methods of recruitment communication, involving 3,800 participants.
• Vanderbilt University Medical Center is sponsoring NCT07674758, "Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials." This study seeks 1,000 participants to better understand the evolution of heart dysfunction in patients with Duchenne and Becker Muscular Dystrophy (DMD/BMD) and Duchenne and Becker muscular dystrophy carriers (MDC).
• Purdue University is leading NCT07620028, "Improving Dietary Quality Through Animal Source Protein Accessibility in a Low-Resource Setting." This study aims to address unmet protein and nutrient requirements during adolescence, involving 500 participants.

Conditions and Types of New Research

New trials this month are exploring a range of conditions, with the most frequent being obesity (3 trials) and type 1 diabetes (2 trials). Other conditions include becker muscular dystrophy, cardiomyopathy, carrier of duchenne muscular dystrophy, CFTR gene mutation, chronic kidney disease, 3b and 4, cystic fibrosis (CF), diabetes mellitus, type 2, and diagnoses of depression, each with 1 new trial. Drug trials account for the largest share of new studies, with 8 new drug trials, followed by 3 behavioral studies, 3 device trials, 3 other types, 1 biological trial, and 1 procedure trial.

Leading the Way: Indianapolis Research Facilities

Indianapolis is home to several prominent research institutions that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Indiana University (99 trials)
• Riley Hospital for Children (66 trials)
• Indiana University School of Medicine (41 trials)
• Indiana University/Melvin and Bren Simon Cancer Center (41 trials)
• Indiana University Melvin and Bren Simon Comprehensive Cancer Center (29 trials)
• Indiana University Health University Hospital (20 trials)
• Saint Catherine Hospital (20 trials)
• Indiana University Health (19 trials)
• Research Site (17 trials)
• IU Health Methodist Hospital (17 trials)
• Community Health Network (16 trials)
• Franciscan Health Indianapolis (15 trials)

These institutions offer a broad spectrum of research, from pediatric care at Riley Hospital for Children to comprehensive medical and cancer research at the various Indiana University facilities.

Who Can Participate?

For individuals without a specific medical condition, there are significant opportunities to contribute to research. Of the 18 new trials launched this month, 2 are actively seeking healthy volunteers. Across Indianapolis, a total of 71 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Participation in clinical trials is open to a diverse range of individuals. Of the new trials launched this month, 6 include children and 15 include older adults, ensuring that these populations have ample opportunity to contribute to medical science. Academic institutions continue to play a vital role in Indianapolis's research ecosystem, with Indiana University sponsoring 5 of the new trials. Industry sponsors like Novo Nordisk A/S (3 trials) are also driving significant research efforts.

Expanding Your Search: Nearby Indiana Cities

While Indianapolis offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Indiana. Cities with active trials include Bloomington (2 trials), Carmel (1 trial), Ellettsville (1 trial), and Muncie (1 trial).

As we move through June, Indianapolis's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.